Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:47:26 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



Q:MRNA - MODERNA INC - https://www.modernatx.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MRNA - Q1.3111.34·111.450.1111.42+3.453.21,234.7136,31316,456108.78  112.33  108.72142.79  62.5512:28:00Apr 2515 min RT 2¢

Recent Trades - Last 10 of 16456
Time ETExPriceChangeVolume
12:28:09Q111.403.4330
12:28:02Q111.3953.4258
12:28:00Q111.373.402
12:28:00Q111.373.407
12:28:00Q111.373.402
12:28:00Q111.44083.47087
12:27:59Q111.403.431
12:27:59Q111.373.405
12:27:57Q111.51343.5434400
12:27:57Q111.51343.5434100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-25 07:02U:MRNANews ReleaseModerna To Present Respiratory & Cytomegalovirus Research at the ESCMID Global Congress
2024-04-24 08:45U:MRNANews ReleaseModerna and OpenAI Collaborate To Advance mRNA Medicine
2024-04-22 07:04U:MRNANews ReleaseModerna Announces Contract with Brazil to Supply 12.5 million COVID-19 Vaccines as Part of National Vaccination Campaign
2024-04-17 07:02U:MRNANews ReleaseModerna to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
2024-04-03 11:05U:MRNANews ReleasePhase 1/2 Interim Data on Moderna's mRNA-3927, an Investigational mRNA Therapy for Propionic Acidemia, Published in Nature
2024-03-27 06:32U:MRNANews ReleaseModerna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
2024-03-26 07:03U:MRNANews ReleaseModerna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
2024-02-29 07:03U:MRNANews ReleaseModerna to Host Fifth Annual Investor Event For Vaccines and Business Updates on March 27, 2024
2024-02-28 07:02U:MRNANews ReleaseModerna to Present at Upcoming Investor Conferences in March 2024
2024-02-22 06:42U:MRNANews ReleaseModerna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
2024-02-07 09:15U:MRNANews ReleaseModerna Chief Executive Officer St ƒ ©phane Bancel Elected to National Academy of Engineering
2024-02-01 07:02U:MRNANews ReleaseModerna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
2024-01-31 17:46U:MRNANews ReleaseModerna Named to Fortune's List of World's Most Admired Companies
2024-01-08 07:03U:MRNANews ReleaseModerna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
2023-12-20 16:08U:MRNANews ReleaseModerna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-15 08:01U:MRNANews ReleaseModerna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company ¢ € ™s Investigational Respiratory Syncytial Virus (RSV) Vaccine
2023-12-14 07:00U:MRNANews ReleaseFirst In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration
2023-12-14 06:32U:MRNANews ReleaseModerna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Comp
2023-12-12 08:01U:MRNANews ReleaseModerna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025